Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Description complète

Détails bibliographiques

Auteurs principaux:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2020-07-01
Collection:	Endocrinology, Diabetes & Metabolism
Sujets:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Accès en ligne:	https://doi.org/10.1002/edm2.159
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!